Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy

J Immunol. 2006 Jun 15;176(12):7726-35. doi: 10.4049/jimmunol.176.12.7726.

Abstract

Proper T cell function relies on the integration of signals delivered by Ag, cytokine, and costimulatory receptors. In this study, the interactions between IL-2, CD27, and its ligand CD70 and their effects on human T cell function were examined. Unstimulated CD8(+) T cells expressed relatively low levels of CD70 and high levels of CD27. Incubation in vitro with high doses of IL-2 (3,000 IU/ml) or administration of IL-2 in vivo resulted in substantial up-regulation of CD70 expression and the concomitant loss of cell surface CD27 expression on CD8(+) cells. Withdrawal of IL-2 from activated CD8(+) T cells that had been maintained in IL-2 resulted in a reversal of the expression of these two markers, whereas reciprocal changes were seen following treatment of PBMCs with IL-2. The proliferation observed in cells stimulated with IL-2 primarily occurred in a subset of the CD70(+)CD8(+) T cells that up-regulated IL-2 receptor expression but did not occur in CD70(-)CD8(+) T cells. Blocking CD70 resulted in a significant reduction of T cell proliferation induced by high-dose IL-2, indicating that the interaction of CD70 with CD27 played a direct role in T cell activation mediated by IL-2. Finally, studies conducted on tumor-infiltrating lymphocyte (TIL) samples that were administered to melanoma patients indicated that the size of the pool of CD27(+)CD8(+) T cells in bulk TILs was highly associated (p = 0.004) with the ability of these TILs to mediate tumor regression following adoptive transfer.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Antigens, CD / biosynthesis*
  • Antigens, CD / genetics
  • Antigens, CD / metabolism
  • CD27 Ligand
  • CD8-Positive T-Lymphocytes / cytology
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / metabolism
  • Cell Proliferation
  • Cells, Cultured
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / metabolism
  • Interleukin-2 / physiology*
  • Lymphocyte Activation / immunology
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / metabolism
  • Lymphocytes, Tumor-Infiltrating / transplantation
  • Melanoma / immunology*
  • Melanoma / pathology
  • Melanoma / therapy*
  • Membrane Proteins / biosynthesis*
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Protein Binding / immunology
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / biosynthesis*
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / genetics
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / metabolism
  • Tumor Necrosis Factors / biosynthesis*
  • Tumor Necrosis Factors / genetics
  • Tumor Necrosis Factors / metabolism
  • Up-Regulation / immunology

Substances

  • Antigens, CD
  • CD27 Ligand
  • CD70 protein, human
  • Interleukin-2
  • Membrane Proteins
  • Tumor Necrosis Factor Receptor Superfamily, Member 7
  • Tumor Necrosis Factors